Vaxcyte Appoints Chief Legal Officer; Narrows VAX‑31 Data Timing

What Happened

• Vaxcyte, Inc. filed a Form 8-K reporting that on August 31, 2026 it appointed David McAvoy as the company's Chief Legal Officer, Chief Compliance Officer and Corporate Secretary. The filing notes that Mikhail Eydelman will continue to serve as Senior Vice President, General Counsel.
• The company also issued a press release on September 3, 2026 titled "Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data," which the 8-K furnished as Exhibit 99.1.

Key Details

• Appointment date: August 31, 2026 (David McAvoy named CLO, CCO, and Corporate Secretary).
• Ongoing role: Mikhail Eydelman remains SVP, General Counsel.
• Press release issued: September 3, 2026; headline announces a CMO appointment and that Vaxcyte narrowed guidance for expected VAX‑31 OPUS‑1 topline data.
• Exhibit: Press release furnished as Exhibit 99.1 to the Current Report on Form 8‑K.

Why It Matters

• Executive changes in legal and compliance are material governance updates investors watch because they can affect regulatory oversight and corporate controls.
• The press release headline also signals an operational update on VAX‑31 OPUS‑1 clinical timing (narrowed guidance), which is relevant for investors tracking the company’s vaccine development milestones and potential upcoming news flow. The 8‑K itself provides the official record of these announcements.